Kanglaite

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameKanglaite
Drug Alias NameKLTiKLTcKLTKanglaite
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCell cycle inhibitorsApoptosis-mediating surface antigen FAS stimulantsApoptosis stimulants +[4] 
TargetsApoptosis regulator Bcl-2Apoptosis-mediating surface antigen FAS
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungLiver Neoplasms
Approved Indications in ChinaCarcinoma, Non-Small-Cell LungLiver Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date1997/01/01
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhejiang Kanglaite Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Kanglaite Pharmaceutical Co Ltd
Inactive CompaniesKanglaite Usa
Active IndicationsCarcinoma, Non-Small-Cell LungLiver Neoplasms
Inactive IndicationsSolid tumoursProstatic NeoplasmsNeoplasms

Other Information

ATC CodeL01
Related LinksN/A